Identification of determinants of long-term disease burden in people with meningioma and the development of prediction models can help early identification of patients at risk for long-term health-related quality-of-life (HRQoL) or neurocognitive impairment. This can facilitate tailored provision of information and the appropriate allocation of supportive care to those most likely to benefit.
Why this matters
Although meningioma is generally a treatable disease, many patients experience long-term impairments affecting HRQoL and neurocognitive function. Being able to predict the patients most likely to be affected by these impairments allows more efficient use of supportive care resources.